华蟾素联合多西他赛单药化疗治疗高龄晚期非小细胞肺癌的临床探讨  

Clinical Study of Cinobufacini Injection Combined With Docetaxel Chemotherapy in the Treatment of Elderly Patients With Advanced Non-small Cell Lung Cancer

作　　者：刘峰林 

机构地区：[1]徐州市中医院肿瘤科,江苏徐州221003

出　　处：《中国继续医学教育》2016年第35期164-165,共2页China Continuing Medical Education

摘　　要：目的 探讨华蟾素联合多西他赛单药化疗治疗高龄晚期非小细胞肺癌的临床疗效。方法 选择2014年3月-2016年8月本院收治的48例高龄晚期非小细胞肺癌患者作为受试者,随机分为对照组（24例）和观察组（24例）。对照组采用多西他赛单药方案,观察组在对照组基础上增加华蟾素治疗,观察两组疗效及不良反应情况。结果 观察组总有效率（62.50%）高于对照组（41.67%）,组间对比,差异具有统计学意义（P〈0.05）。观察组不良反应发生率与对照组比较,差异无统计学意义（P〉0.05）。结论 高龄晚期非小细胞肺癌患者多西他赛单药化疗方案中联合应用华蟾素可显著提高治疗效果,且安全性良好。Objective To investigate the clinical curative effect of cinobufacini injection combined with docetaxel chemotherapy in the treatment of elderly patients with advanced non-small cell lung cancer. Methods 48 cases of elderly patients with advanced non small cell lung cancer were randomly divided into the control group（24 cases） and the observation group（24 cases）, which were selected from March 2014 to August 2016. The control group was using about docetaxel monotherapy, the observation group, based on the control group, was the increase of cinobufacini treatment, and adverse reactions were observed two groups of curative effect. Results The total effective rate（62.50%） in the observation group was significantly higher than that in the control group（41.67%）, and the difference between two groups was statistically significant（P〈0.05）. The incidence of adverse reactions in the observation group compared with the control group, there was no significant difference between two group（P〈0.05）. Conclusion Elderly patients with advanced non small cell lung cancer treated with docetaxel single agent chemotherapy combined with cinobufacin can significantly improve the therapeutic effect and good safety.

关 键 词：肺癌 非小细胞癌 高龄 华蟾素 多西他赛 

分 类 号：R734.2[医药卫生—肿瘤]